Each Year in the U.S.:
With ongoing and consistent advocacy for antimicrobial stewardship, bioMérieux aims to support the evolution of antibiotic prescribing practices. We partner with healthcare systems to provide a complete solution that supports the continuous improvement of antimicrobial stewardship programs.
Diagnostics and Antimicrobial Stewardship
Antimicrobial stewardship is a commitment to preserving drug efficacy for future generations through appropriate use of antimicrobial drugs. While everyone has a role to play in antimicrobial stewardship, healthcare and industry professionals are at the forefront of the fight against antimicrobial resistance.
Antimicrobial Stewardship in Healthcare Settings
Antimicrobial stewardship programs provide a framework for healthcare systems to better protect patients from the harms of unnecessary antibiotic use and antimicrobial resistance. According to the CDC, roughly 85% of U.S. acute care hospitals have antimicrobial stewardship programs that rely on the CDC’s seven Core Elements of Hospital Antibiotic Stewardship. As a leader in the field of in vitro diagnostics and antimicrobial stewardship, bioMérieux partners with U.S. healthcare systems to enhance the continuum of care and increase the economic value of stewardship. To do so, we integrate fast and actionable diagnostics, expert consultancy services, and an unmatched advanced analytic platform.
bioMérieux is the trusted partner that today’s healthcare systems need to confidently deliver improved clinical outcomes and support stewardship programs.
Diagnostics and data-driven tools help clinicians determine appropriate treatment and reduce the spread of antibiotic-resistant infections. bioMérieux’s integrated offer provides healthcare institutions with information and resources needed to effectively combat antimicrobial resistance and can help initiate sustainable momentum for developing and optimizing stewardship programs. 80% of our existing diagnostic products and 75% of our research and development budget are dedicated to the fight against antimicrobial resistance.
DIAGNOSTICS TO IMPROVE ANTIBIOTIC USE
An accurate and early diagnosis can play a decisive role in patient outcomes by improving appropriate antibiotic selection and reducing unnecessary antibiotic use. Our diagnostic systems help clinical labs reduce the time required for detection, identification, and susceptibility testing.
CONSULTANCY SERVICES TO ADVANCE STEWARDSHIP INITIATIVES
With a deep expertise in microbiology and infectious diseases, our collaborative Lab Optimization Consultancy and Stewardship Consultancy help our partners to understand their real processes—then visualize, analyze, and apply data, to support positive patient outcomes. Our partnership approach reveals best practices that can improve patient care, and contribute to economically sustainable healthcare systems by creating ways to keep costs under control.
Lab Optimization Consultancy
Relevant and timely results have become key in the race to be more efficient and control costs. With our patient-centric approach, we help laboratories optimize and transform their workflow to support clinical decisions and better patient outcomes. This elevates the important role the laboratory plays in the value-based healthcare model.
DOWNLOAD THE LAB OPTIMIZATION BROCHURE
Our customer-centric approach, teamed with our extensive knowledge and experience, means that we see things from a unique angle and can provide consultancy to support stewardship programs with cross-departmental impact. We point hospitals in the right direction with an executable Antimicrobial Stewardship Roadmap to help organizations discover dynamic insights and drive action.
ADVANCED ANALYTICS TO SUPPORT TIMELY CLINICAL DECISIONS
Fighting Antimicrobial Resistance is Everyone’s Concern
While it may be easy to see why combatting antimicrobial resistance requires healthcare professionals to develop and sustain antimicrobial stewardship programs, the roles of other people in society may be less obvious. However, reducing the spread of antimicrobial resistance requires attention and action from policy makers, governmental authorities, and even patients and caretakers.
bioMérieux is actively engaged in activities that support the multipronged approach that is needed to mitigate the rise of antimicrobial resistance. Through industry partnerships, ongoing advocacy for diagnostics at the government and policy levels, and development of educational resources for both professionals and patients, bioMérieux continues to expand our impact outside of the clinical laboratory.
AMR and Stewardship Resources
Stewardship Education Opportunities
External Partner Resources
As a proud member of the AMR Industry Alliance, we invite you to view their 2020 Progress Report which provides a snap shot of the life sciences industry's collective efforts and leadership in tackling the rise of antimicrobial resistance.
In November 2019, the Centers for Disease Control updated their Core Elements of Hospital Antibiotic Stewardship Programs to reflect key learnings and evidence, further advancing the viability of stewardship programs in the U.S.
As a grant supporter of the Antimicrobial Stewardship Project (ASP), we encourage you to visit the Center for Infectious Disease Research and Policy's ASP page to view the latest industry news and updates about stewardship in the U.S.
The AMR Challenge was a yearlong effort by the U.S. government to accelerate the fight against AMR. bioMérieux is proud to have been a participant and to have helped promote and enourage the one health approach.
- Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Available at https://amr-review.org/sites/default/files/AMR. Accessed on Sep. 23, 2020.
- Clancy CJ, Ngguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clinical Infectious Dis 2020. doi/10.1093/cid/ciaa524/5828436.
- Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Available at: cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed Sep. 3, 2020.
PRN 057494 Rev01.B